Abstract. To evaluate the clinical usefulness of serum soluble Fas (sFas) and sFas ligand as a prognostic factor and for monitoring the regression and progression of metastatic prostate cancer treated with endocrine therapy, sFas and sFas ligand were measured in sera collected from 30 patients with untreated metastatic prostate cancer. sFas levels were measured sequentially in 16 patients who had progressed to a state of elevated prostate-specific antigen (PSA) and 5 patients who were in regression following endocrine therapy. Serum sFas levels in patients with metastatic prostate cancer were found to be significantly higher than that of control patients with benign prostate hyperplasia. Patients with low levels of serum sFas had a higher cause-specific survival rate and a higher PSA progression-free rate compared with patients with high levels of serum sFas. In patients who suffered PSA progression following endocrine therapy, serum sFas increased in parallel to the increase in PSA levels although the magnitude of change in sFas was very small. In patients whose tumor regressed following therapy, sFas levels did not change. sFas ligand levels were very low or below measurable levels in all specimens. sFas levels might be associated with poor prognosis in metastatic prostate cancer. Serum sFas ligand appears to have limited clinical relevance.
FAS/APO-1/CD95 has been known as a transmembrane protein and a member of the tumor necrosis factor (TNF) receptor family [1] . The Fas-Fas ligand system plays an important role in cytotoxic Tlymphocyte-mediated and natural killer cell-mediated cytotoxicity against cancer cells [2, 3] . Both Fas and Fas ligand exist as membrane bound and soluble forms [4, 5] . Soluble Fas (sFas), which lacks the transmembrane domain, is produced by alternative splicing of Fas mRNA [6] . sFas binds to and neutralizes Fas ligand, thereby functionally antagonizing the Fas-Fas ligand pathway [6] . Recently serum sFas has been reported to be elevated in patients with malignant diseases including prostate cancer [7] [8] [9] [10] [11] [12] [13] . Patients diagnosed with prostate cancer have also been shown to have significantly higher levels of serum sFas than those with benign prostate hyperplasia [13] . The serum level of sFas has been reported to be significantly elevated in patients with metastatic prostate cancer [13] .
Cleavage of the TNF homologous portion of the membrane Fas ligand into a soluble form by a metalloprotease has recently been reported [14] . Circulating isoforms of Fas ligand might prevent the recognition of tumor cells by the cytotoxic T-cells by imitating tumor cells as immune-privilege sites [15] . The serum concentration of sFas ligand has been noted in patients with lymphoma, nonhematopoietic malignancy, and hepatocellular carcinoma [11, 16, 17] . As apoptosis plays an important role in the development and homeostasis of multicellular organs, the failure of cells to undergo apoptosis might be involved in the pathogenesis of a variety of human diseases including cancers. In the present study, we examined serum sFas and sFas ligand levels in patients with metastatic prostate cancer. We showed that the value of sFas as a prognostic factor in metastatic prostate cancer. Subsequent changes of sFas during the course of prostate cancer were also examined.
Materials and Methods
Sera were collected from 30 and 19 patients with untreated metastatic prostate cancer and benign prostate hyperplasia (BPH), respectively and were separated within a few hours after phlebotomy and stored at -70°C prior to determining the presence and/or concentrations of sFas, sFas ligand and prostate-specific antigen (PSA). The age of the patients examined in this study ranged from 58 to 87 years, with a mean age of 75 years (metastatic prostate cancer patients) and from 52 to 82 years, with a mean of 68 (BPH patients). Informed consent was obtained from all patients to participate in all procedures associated with this study. Patients who had received digital rectal examination or other prostatic manipulation during the study were excluded from the study. All patients were pathologically diagnosed with prostate cancer or BPH following a transrectal ultrasonography guided systematic biopsy.
In 30 patients with metastatic prostate cancer, bone was the major site(s) of metastasis (30 patients) with additional metastases to the lymph nodes in four patients. The histological grade of all tumors was evaluated according to the classification of General Rule for Clinical and Pathological Studies on Prostatic Cancer [18] in which 15 patients were diagnosed with moderately-differentiated adenocarcinoma and 15 patients were diagnosed with poorly-differentiated adenocarcinoma. The extent of bone metastasis (EOD) was classified according to the methods described by Soloway et al. [19] . Endocrine therapy applied to all prostate cancer patients consisted of castration (surgical procedure or administration of LHRH analogue) combined with antiandrogens (chlormadinone acetate or flutamide).
Sera were collected sequentially during PSA progression from 16 cancer patients whose PSA had elevated following the initial response to endocrine therapy. PSA was measured every other month. When PSA levels increased, PSA was measured every month. PSA progression was defined as the first day of three consecutive rises of PSA levels in spite of castrated serum testosterone level. Patient characteristics are shown in Table 1 . Median duration of therapy (from initial endocrine treatment to the first determination of sFas) was 28 months (range 6-96). In five patients with metastatic prostate cancer, sFas was measured one month before and after endocrine treatment. Serum sFas levels were measured using an enzymelinked immunosorbent assay (ELISA, MBL, Nagoya, Japan) according to the manufacturer's instructions. The sensitivity of the test was 0.5 ng/ml; intra-and interassay variability were less than 7.1% and less than 7.3%, respectively. In measuring serum sFas ligand, an ELISA kit (MBL) was used according to the manufacturer's instructions. The sensitivity of the test was 0.1 ng/ml; intra-and interassay variability were less than 7.4% and less than 10.7%, respectively. Serum PSA levels were measured using a Tosoh II kit (Tosoh Corp, Tokyo, Japan). Data are shown as mean ± SD. The statistical significance of differences of PSA and sFas during treatment was analyzed using a Wilcoxon signed rank test. Survival curves were calculated by the Kaplan-Meier method and statistical significance was estimated by the Cox-Mantel method. Multivariate analysis was performed by a Cox proportional hazard model. P<0.05 was considered statistically significant.
Results
Serum PSA and sFas levels in 30 untreated patients with metastatic prostate cancer were 695 ± 927 ng/ml (range, 4.3-3000) and 3.67 ± 1.55 ng/ml (range, 1.95-10.0), respectively. Serum PSA and sFas levels in 19 BPH patients, which served as controls, were 6.9 ± 4.6 ng/ml (range, 0.5-18) and 2.18 ± 0.75 ng/ml (range, 1.15-3.90), respectively. Serum sFas in metastatic prostate cancer was higher (p = 0.0004) than in BPH patients. In order to examine whether sFas levels might indicate a patients' prognosis, survival curves of 30 patients were depicted. Mean follow-up periods were 14.3 months (range, 4-38). The cause-specific survival rate was significantly higher in the group showing a sFas level < 3.2 ng/ml (less than the median value) than in the group showing a level 3.2 ng/ml (Fig. 1, p = 0.047) . Because the follow up period was short, PSA progression-free survival was examined. Like cause-specific survival, PSA progression-free survival rate was found to be significantly higher in the group showing a sFas level < 3.2 ng/ml than in the group showing a level ³3.2 ng/ml (Fig. 2 , p = 0.031). According to univariate analysis, the extent of bony disease (EOD 0,1,2 vs. EOD 3,4) was another significant prognostic factor of cause-specific survival (p = 0.0076). Multivariate analysis was performed using sFas levels and EOD as variables. These variables were not significant prognostic factors in multivariate analysis. Serum sFas ligand levels in all samples were below measurable limits, suggesting that there was no soluble sFas ligand present in the evaluated patients.
Sera were obtained from16 patients with metastatic prostate cancer during PSA progression. All of them had initially responded to endocrine therapy, subse- quently serum PSA levels increased. During PSA progression, changes in the serum PSA and sFas were sequentially measured ( Table 1) . The range and median of interval from the first and second PSA/sFas determination was 3-18 and 7 months, respectively. Serum PSA levels increased from 39.2 ± 78.4 to 503 ± 1498 ng/ml (p<0.001). Serum sFas levels increased from 3.23 ± 0.66 to 3.61 ± 0.98 ng/ml although the difference was not statistically significant (p = 0.087). These results suggest that changes in serum sFas parallels that of PSA levels although the magnitude of these changes in sFas was very small. In five patients with metastatic prostate cancer sFas and PSA were determined before and one month after endocrine treatment. Although serum sFas levels did not change (from 3.89 ± 1.29 to 3.68 ± 0.67 ng/ml, p = 0.89), serum PSA levels decreased from 143 ± 100 to 15.6 ± 3.7 ng/ ml (p = 0.043).
Discussion
sFas is generated by alternative mRNA splicing [6] . Because sFas could functionally antagonize Fas ligand to effectively inactivate cell surface Fas function, failure of Fas triggering may prolong the survival of tumor cells and lead to the development and progression of malignancy [6] . sFas may function as an inhibitor of the Fas/Fas ligand system, and escape of tumor cells from immune surveillance may also occur. The chimeric sFas fusion molecule, which is composed of the extracellular domain of Fas and the Fc portion of human IgG, abrogates Fas-dependent CTL activity [20] . Recently an elevated soluble form of Fas has been identified in the serum of patients with cervical, ovarian, bladder, renal cell, colon, breast and hepatocellular cancer [7] [8] [9] [10] [11] [12] . The sFas levels in patients with prostate cancer have been reported to be significantly higher than those without cancer [13] . Pretreatment serum sFas levels have been suggested to be a prognostic factor in some kinds of tumors [7] [8] [9] . Although the observation period in the present study was very short, patients with higher pretreatment sFas levels were shown to have worse cause-specific survival and PSA progression-free rates than those with lower sFas levels. There have been no reports describing the prognostic significance of serum sFas levels in patients with prostate cancer.
The precise cellular origin of increased sFas in the serum remains unclear. Judo et al. reported that surgical removal of a hepatocellular carcinoma reduced sFas levels to negative values within the first postoperative week [12] . Nonomura et al. also reported that sFas levels in patients with renal cell cancer were correlated with tumor size and significantly decreased following nephrectomy [10] . Prostate cancer specimens have been reported to express Fas antigen by immunohistochemical analysis [21] . Bladder cancer cell lines have been reported to produce sFas [22] . From those observations, sFas might be produced, at least in part, by the tumor cells. However, although PSA levels decreased in the present study, sFas did not decrease one month after endocrine treatment. The reason why sFas levels did not change might be due to the short observation period following endocrine therapy. A longer post-therapy observation period (i.e. 3-6 months) may be required to see if sFas levels decrease. Cultured renal cell cancer cells did not produce sFas into the culture supernatant [10] . It has been reported that sFas is produced elsewhere in response to a tumor and that elevation of sFas reflects the tumor burden in renal cell cancer [10] . sFas might be produced by activated lymphocytes and stromal tissues surrounding the tumor in response to immune activation. Mizutani et al. demonstrated that there was an inverse correlation between the level of sFas in the serum and the magnitude of anti-autologous tumor cytotoxicity [9] . An evasion of the host immune surveillance might be important for disease progression when cancer cells enter into the blood circulation. In patients with prostate cancer, we could not identify any direct correlation between sFas levels and tumor burden. Further studies with a larger patient population are required to confirm these findings.
The biologic significance of serum sFas ligand in malignant tumors is currently unknown. It has been reported that serum levels of sFas ligand in advanced gastric cancer patients are higher than those of healthy controls and patients with early stage gastric cancer [14] . On the contrary, Perabo et al. reported no measurable sFas ligand in the sera obtained from healthy controls and bladder cancer patients [22] . In the present study, we could not detect serum sFas ligand in patients with metastatic prostate cancer and BPH using the same ELISA kit with which Tsutsumi et al. measured the sera of gastric cancer patients [15] . To our knowledge, there have been no reports concerning sFas ligand in patients with prostate cancer.
In conclusion, serum sFas levels in patients with metastatic prostate cancer are elevated and might be an indicator of tumor progression. Serum sFas ligand has limited clinical value for tumor markers in prostate cancer.
